The Advances in Gastrointestinal Cancer Resource Centre Introduction
The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting edge data to practising healthcare professionals. Our aim is to provide clinically relevant information in order to enhance the caregivers' ability to provide optimal care for their gastrointestinal (GI) cancer patients. We will offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, will function as a hub of information for healthcare professionals.
Our initial focus for Advances in Gastrointestinal Cancer will centre on gastric cancer, with future expansion to all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
Expert interviews from ESMO World Congress on Gastrointestinal Cancer
Article of the month
Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced or recurrent gastric cancer (JFMC45-1102)
Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, et al.
Int J Cancer 2016 Aug 13. [Epub ahead of print]
Selected and commented by Professor David Cunningham:
In this study, Japanese investigators examined the efficacy of 2nd line trastuzumab plus paclitaxel in gastric cancer patients with HER2 positive tumours. Of note, although patients had received prior chemotherapy, they were trastuzumab naïve. The objective radiological response rate was 37% and progression free and overall survival in this trial were survival were 5.1 (95% CI 3.8–6.5) and 17.1 (95% CI 13.5–18.6) months, respectively. These results are encouraging but there are several important caveats which must be considered...
Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L.World J Gastroenterol 2016 Jul 14;22(26):5879-87.
Chan BA, Jang RW, Wong RK, Swallow CJ, Darling GE, Elimova E.Oncology (Williston Park) 2016 Jul;30(7):635-45. Review.
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
Shah MA, Cho JY, Tan IB, Tebbutt NC, Yen CJ, Kang A, et al.Oncologist. 2016 Jul 8. [Epub ahead of print]
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
Davidson M, Smyth EC, Cunningham D.Onco Targets Ther 2016;9:4539–48.
Eradication of Helicobacter pylori and Gastric Cancer: A Systematic Review and Meta-analysis of Cohort Studies
Doorakkers E, Lagergren J, Engstrand L, Brusselaers N.J Natl Cancer Inst 2016 Jul 14;108(9)